Alebund Pharmaceuticals Holds Groundbreaking Ceremony for Yangzhou Research and Production Base

Yangzhou, China, Dec. 7, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, held today a groundbreaking ceremony for its research and production plant in Jiangsu province’s Yangzhou city.

The new plant, located in the bio-industrial park of Yangzhou high-tech zone, will significantly enhance the company’s production capacity for medicines related to chronic renal failure and dialysis complications. The first phase of the project, with an investment of about 1 billion yuan, covers 107 mu of land and construction area of 74,000 square meters. The project, which will produce AP-301 and AP-306 for the treatment of hyperphosphatemia, is expected to be fully completed by the end of 2024.

Chronic kidney disease (CKD) has become a prominent public health problem. The prevalence rate of CKD in China is as high as 10.8%, and the incidence and mortality are increasing year by year, underlining huge unmet medical demand in this field. After the dedicated efforts over last three years, Alebund Pharmaceutical has established a rich and diversified product pipeline. The company’s most clinically advanced product, which has best-in-class potential in the treatment of hyperphosphatemia, is currently under Phase II clinical trial and is expected to start Phase III registrational study in 2022.

Zhang Baojuan, Yangzhou municipal party secretary, said: “China is vigorously implementing the strategy to promote the healthcare industry, which represents a major development opportunity. The Yangzhou government is also working hard to build an influential and competitive manufacturing production base as well as a technological innovation base in the Yangtze River Delta region. The new research and production plant of Alebund Pharmaceuticals is an important step in the company’s development, and also a new driving force for quality and efficiency among industrial projects in Yangzhou. We look forward to deepening cooperation with Lilly Asia Ventures and Alebund Pharmaceuticals to promote more high-quality projects in Yangzhou. I’d like to extend my best wishes to the construction of Alebund’s new research and production base and hope the project can run at full capacity as soon as possible.”

Zhang Yaowu, member of the Standing Committee of the Yangzhou Municipal Party Committee and party secretary of the Hanjiang District, said: “The Alebund research and production project that marked groundbreaking today is an important achievement of investment promotion in the Hanjiang district. After completion, it will become an integrated plant with research, API and drug manufacturing. As China’s first biopharmaceutical company focusing on the development of novel renal therapies, Alebund Pharmaceuticals has received investment from Lilly Asia Ventures and many other financial institutions, and has advanced technical equipment as well as clinical development capabilities. We believe that the cooperation between Alebund and Hanjiang will enter a new stage, and Alebund’s development will definitely accelerate and become more prosperous. The relevant departments of Yangzhou High-tech Zone will maintain their high efficiency seen previously and continue to provide thoughtful and timely services to ensure that the project will complete construction and enter operation ahead of schedule.”

Dr. Chutian Shu, Chief Technology Officer of Alebund and General Manager of Alebund Biopharmaceuticals (Jiangsu) Ltd., said, “The construction of a research and production base in Yangzhou is a major milestone for Alebund to become a fully-fledged biopharmaceutical company with research, clinical development and manufacturing capabilities. Building our own production capacity will bring us advantages in cost and quality control and ensure drug supply, achieve the goal of bringing quality and affordable medicines to patients in need, and accelerate our drive to become a global leader in novel therapies for chronic renal diseases. Due to the large patient population, numerous complications, and limited treatment options that are safe and effective, there is a significant unmet medical need for novel therapies in chronic renal diseases. We’d like to thank leaders in Yangzhou government for their support and we’ll work together to benefit renal patients both in China and globally.”

About Alebund Pharmaceuticals

Alebund is a clinical stage biopharmaceutical company and is dedicated to the discovery and development of novel therapies and to providing better clinical solutions to patients with kidney diseases and related chronic conditions.

Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease /dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund’s pipeline comprises both small-molecule and biologic assets.


(中国扬州,2021 年 12 月 7 日)礼邦医药,一家致力于肾脏病以及相关慢性病药物研发的生物制药公司,今日宣布扬州肾脏疾病领域新药研发生产基地项目正式奠基。新建基地将显著提升公司在慢性肾衰和透析并发症相关药物的产业化生产能力。

新建研发生产基地位于扬州高新区生物健康产业园内,一期项目投资约 10 亿元,一次性征地约 107 亩,建筑面积达 74000 平方米,用于生产高磷血症药品 AP-301 和 AP-306,预计于 2024 年底前全面建成投产。

慢性肾脏病已成为突出的公共健康问题,而中国慢性肾脏病患病率高达 10.8%,且患病率与病死率逐年升高, 显示着该领域极大的未被满足的患者需求。经过三年的快速发展,礼邦医药已经建立起了丰富的产品管线,研发进度最快的治疗高磷血症的产品 AP-301 目前正进行临床二期试验,该产品具备全球同类最佳潜力,计划于 2022 年启动三期注册性临床研究。





礼邦医药是一家处于临床阶段的生物制药公司,具有强大的新药研发和临床开发能力。公司主要致力于肾脏病以及其他相关慢性疾病的创新药物发现和开发,为肾脏病及相关慢性疾病患者提供更佳的临床解决方案。礼邦医药已经建立起了丰富且均衡的肾脏病新药产品管线,包括针对慢性肾脏病/透析并发症,IgA 肾病,糖尿病肾病和常染色体显性多囊肾病等产品,公司同时拥有小分子药物和生物制剂在研。